Regulus Therapeutics Inc. - Common Stock (NQ:RGLS)

8.160 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regulus Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders

May 15, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq

May 15, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

May 04, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

May 01, 2025

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancorp, Inc.

May 01, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗

May 01, 2025

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a...

Via Stocktwits

Topics Stocks

Wednesday's session: top gainers and losers ↗

April 30, 2025

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Top stock movements in today's session. ↗

April 30, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 30, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

April 30, 2025

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher ↗

April 30, 2025

Via Benzinga

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million ↗

April 30, 2025

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025.

Via Benzinga

These stocks that are showing activity before the opening bell on Wednesday. ↗

April 30, 2025

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results ↗

April 30, 2025

Via Benzinga

Topics Stocks

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis ↗

April 30, 2025

According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million.

Via Stocktwits

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders

April 30, 2025

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 30, 2025

Via Benzinga

Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders

April 30, 2025

From Ademi & Fruchter LLP

Via Business Wire

Top movers analysis one hour before the close of the markets on 2025-04-28: top gainers and losers in today's session. ↗

April 28, 2025

Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

These stocks are moving in today's session ↗

April 28, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

These stocks have an unusual volume in today's session ↗

April 01, 2025

Volume analysis on 2025-04-01: stocks with an unusual volume in today's session.

Via Chartmill

Top stock movements in today's session. ↗

March 27, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 27, 2025

Via Benzinga

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease ↗

March 27, 2025

Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable safety profile.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 27, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

February 04, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Here are the top movers in Wednesday's session. ↗

January 29, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024 ↗

August 09, 2024

RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 25, 2024

Via Benzinga

What's Going On With Regulus Therapeutics Stock Monday? ↗

June 24, 2024

Regulus Therapeutics announced positive results from its study related to the treatment of autosomal dominant polycystic kidney disease (AKPD).

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.